HSC Section 6 Nov2016 Green Book

Otolaryngology–Head and Neck Surgery, Vol 139, No 3, September 2008

Figure 1

Summary of patient flow throughout study. PPI treatment

esomeprazole 20 mg twice daily.

placebo group. Similar to the result of the first follow-up visit, there was a significantly stronger improvement of the symptom heartburn in patients receiving esomeprazole. The comparison of the total RFS reduction between the two study groups reveals a statistically significant difference in favor of the esomeprazole group ( P 0.05). In contrast to esomeprazole recipients, patients receiving placebo did not show any significant improvement of ventricular oblitera-

tion or laryngeal erythema. After a treatment period of three months, the final examination revealed a statistically signif- icant stronger improvement of erythema and diffuse laryn- geal edema in the esomeprazole group ( P 0.05). The most significant difference between the study groups was the much stronger reduction of posterior commissure hypertro- phy in the esomeprazole group after three months of therapy ( P 0.01).

147